Cleavage of the Ewing tumour-specific EWSR1-FLI1 mRNA by hammerhead ribozymes

Anticancer Research

Volumn 29, Issue 6, 2009, Pages 1901-1908

  Hühn, Regina ^a   Staege, Martin S ^a,c   Hesse, Manuela ^a   Liebig, Beate ^a   Burdach, Stefan E G ^b  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

Author keywords

Ewing tumours; EWSR1 FLI1; Ribozymes

Indexed keywords

CHIMERIC PROTEIN; COMPLEMENTARY DNA; HAMMERHEAD RIBOZYME; HYBRID PROTEIN; MESSENGER RNA; RNA; RNA BINDING PROTEIN EWS; TRANSCRIPTION FACTOR FLI 1;

ADOLESCENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CATALYSIS; CONTROLLED STUDY; DRUG DESIGN; DRUG SPECIFICITY; ENZYME INACTIVATION; EWING SARCOMA; GENE AMPLIFICATION; HUMAN; HUMAN CELL; IN VITRO STUDY; POINT MUTATION; PRIORITY JOURNAL; RNA CLEAVAGE; SARCOMA CELL;

BASE SEQUENCE; BONE NEOPLASMS; CALMODULIN-BINDING PROTEINS; HUMANS; MOLECULAR SEQUENCE DATA; NUCLEIC ACID CONFORMATION; ONCOGENE PROTEINS, FUSION; PROTO-ONCOGENE PROTEIN C-FLI-1; RNA, CATALYTIC; RNA, MESSENGER; RNA, NEOPLASM; RNA-BINDING PROTEINS; SARCOMA, EWING'S; SEQUENCE HOMOLOGY, NUCLEIC ACID; TUMOR CELLS, CULTURED;

EID: 67650921954     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Burdach S, van Kaick B, Laws HJ, Ahrens S, Haase R, Körholz D, Pape H, Dunst J, Kahn T, Willers R, Engel B, Dirksen U, Kramm C, Nürnberger W, Heyll A, Ladenstein R, Gadner H, Jürgens H and Göbel U: Allogeneic and autologous stem-cell transplantation in advanced Ewing tumors. An update after long-term follow-up from two centers of the European Intergroup study EICESS. Stem-Cell Transplant Programs at Düsseldorf University Medical Center, Germany and St. Anna Kinderspital, Vienna, Austria. Ann Oncol 11: 1451-1462, 2000.
2. Burdach S, Meyer-Bahlburg A, Laws HJ, Haase R, van Kaik B, Metzner B, Wawer A, Finke R, Göbel U, Haerting J, Pape H, Gadner H, Dunst J and Juergens H: High-dose therapy for patients with primary multifocal and early relapsed Ewing's tumors: results of two consecutive regimens assessing the role of total-body irradiation. J Clin Oncol 21: 3072-3078, 2003. (Pubitemid 46606287)
3. Staege MS, Hutter C, Neumann I, Foja S, Hattenhorst UE, Hansen G, Afar D and Burdach SE: DNA microarrays reveal relationship of Ewing family tumors to both endothelial and fetal neural crest-derived cells and define novel targets. Cancer Res 64: 8213-8221, 2004. (Pubitemid 39491758)
4. Tirode F, Laud-Duval K, Prieur A, Delorme B, Charbord P and Delattre O: Mesenchymal stem cell features of Ewing tumors. Cancer Cell 11: 421-429, 2007. (Pubitemid 46680428)
5. Miyagawa Y, Okita H, Nakaijima H, Horiuchi Y, Sato B, Taguchi T, Toyoda M, Katagiri YU, Fujimoto J, Hata J, Umezawa A and Kiyokawa N: Inducible expression of chimeric EWS/ETS proteins confers Ewing's family tumor-like phenotypes to human mesenchymal progenitor cells. Mol Cell Biol 28: 2125-2137, 2008.
6. Riggi N, Cironi L, Provero P, Suvà ML, Kaloulis K, Garcia-Echeverria C, Hoffmann F, Trumpp A and Stamenkovic I: Development of Ewing's sarcoma from primary bone marrow-derived mesenchymal progenitor cells. Cancer Res 65: 11459-11468, 2005. (Pubitemid 41821703)
7. Richter GH, Plehm S, Fasan A, Rössler S, Unland R, Bennani-Baiti IM, Hotfilder M, Löwel D, von Luettichau I, Mossbrugger I, Quintanilla-Martinez L, Kovar H, Staege MS, Müller-Tidow C and Burdach S: EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation. Proc Natl Acad Sci USA 106: 5324-5329, 2009.
8. Delattre O, Zucman J, Melot T, Garau XS, Zucker JM, Lenoir GM, Ambros PF, Sheer D, Turc-Carel C, Triche TJ, Aurias A and Thomas G: The Ewing family of tumors - a subgroup of small-round-cell tumors defined by chimeric transcripts. N Engl J Med 331: 294-299, 1994. (Pubitemid 24236016)
9. Burdach S and Jürgens H: High-dose chemoradiotherapy (HDC) in the Ewing family of tumors (EFT). Crit Rev Oncol Hematol 41: 169-189, 2002.
10. Dagher R, Long LM, Read EJ, Leitman SF, Carter CS, Tsokos M, Goletz TJ, Avila N, Berzofsky JA, Helman LJ and Mackall CL: Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: an interinstitute NIH study. Med Pediatr Oncol 38: 158-164, 2002. (Pubitemid 34171069)
11. Mackall C, Berzofsky J and Helman LJ: Targeting tumor specific translocations in sarcomas in pediatric patients for immunotherapy. Clin Orthop 373: 25-31, 2000. (Pubitemid 30225656)
12. Meyer-Wentrup F, Richter G and Burdach S: Identification of an immunogenic EWS-FLI1-derived HLA-DR-restricted T helper cell epitope. Pediatr Hematol Oncol 22: 297-308, 2005. (Pubitemid 40770481)
13. Worley BS, van den Broeke LT, Goletz TJ, Pendleton CD, Daschbach EM, Thomas EK, Marincola FM, Helman LJ and Berzofsky JA: Antigenicity of fusion proteins from sarcoma-associated chromosomal translocations. Cancer Res 61: 6868-6875, 2001. (Pubitemid 32896512)
14. Pindolia VK and Zarowitz BJ: Imatinib mesylate, the first molecularly targeted gene suppressor. Pharmacotherapy 22: 1249-1265, 2002. (Pubitemid 35155079)
15. Kovar H, Aryee DN, Jug G, Henockl C, Schemper M, Delattre O, Thomas G and Gadner H: Ews/fli-1 antagonists induce growth inhibition of Ewing tumor cells in vitro. Cell Growth Differ 7: 429-437, 1996. (Pubitemid 26362087)
16. Lambert G, Bertrand JR, Fattal E, Subra F, Pinto-Alphandary H, Malvy C, Auclair C and Couvreur P: Ews/fli-1 antisense nanocapsules inhibits Ewing sarcoma-related tumor in mice. Biochem Biophys Res Commun 27: 401-406, 2000. (Pubitemid 32016729)
17. Tanaka K, Iwakuma T, Harimaya K, Sato H and Iwamoto Y: Ews-fli1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing's sarcoma and primitive neuroectodermal tumor cells. J Clin Invest 9: 239-247, 1997. (Pubitemid 27053464)
18. Toretsky JA, Connell Y, Neckers L and Bhat NK: Inhibition of ews-fli-1 fusion protein with antisense oligodeoxynucleotides. J Neurooncol 31: 9-16, 1997. (Pubitemid 27077704)
19. Tschuch C, Schulz A, Pscherer A, Werft W, Benner A, Hotz-Wagenblatt A, Barrionuevo LS, Lichter P and Mertens D: Off-target effects of siRNA specific for GFP. BMC Mol Biol 9: 60, 2008. (Pubitemid 351959580)
20. Anderson E, Boese Q, Khvorova A and Karpilow J: Identifying siRNA-induced off-targets by microarray analysis. Methods Mol Biol 442: 45-63, 2008.
21. Vankoningsloo S, de Longueville F, Evrard S, Rahier P, Houbion A, Fattaccioli A, Gastellier M, Remacle J, Raes M, Renard P and Arnould T: Gene expression silencing with 'specific' small interfering RNA goes beyond specificity - a study of key parameters to take into account in the onset of small interfering RNA off-target effects. FEBS J 275: 2738-2753, 2008.
22. Karikó K, Bhuyan P, Capodici J and Weissman D: Small interfering RNAs mediate sequence-independent gene suppression and induce immune activation by signaling through toll-like receptor 3. J Immunol 172: 6545-6549, 2004. (Pubitemid 38669088)
23. Hornung V, Guenthner-Biller M, Bourquin C, Ablasser A, Schlee M, Uematsu S, Noronha A, Manoharan M, Akira S, de Fougerolles A, Endres S and Hartmann G: Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med 11: 263-270, 2005. (Pubitemid 40460553)
24. James HA and Gibson I: The therapeutic potential of ribozymes. Blood 91: 371-382, 1998.
25. Birikh KR, Heaton PA and Eckstein F: The structure, function and application of hammerhead ribozyme. Eur J Biochem 24: 1-16, 1997. (Pubitemid 27142257)
26. Rossi JJ and Sarver N: RNA enzymes (ribozymes) as antiviral therapeutic agents. Trends Biotechnol 8: 179-183, 1990. (Pubitemid 20193468)
27. Sullenger BA and Cech TR: Tethering ribozymes to a retroviral packaging signal for destruction of viral RNA. Science 262: 1566-1569, 1993. (Pubitemid 24036113)
28. Dawson PA and Marini JC: Hammerhead ribozymes selectively suppress mutant type I collagen mRNA in osteogenesis imperfecta fibroblasts. Nucleic Acids Res 28: 4013-4020, 2000. (Pubitemid 30784453)
29. Jiang WG, Grimshaw D, Lane J, Martin TA, Abounader R, Laterra J, Mansel RE and Abounder R: A hammerhead ribozyme suppresses expression of hepatocyte growth factor/scatter factor receptor c-MET and reduces migration and invasiveness of breast cancer cells. Clin Cancer Res 7: 2555-2562, 2001. (Pubitemid 32751662)
30. Pavco PA, Bouhana KS, Gallegos AM, Agrawal A, Blanchard KS, Grimm SL, Jensen KL, Andrews LE, Wincott FE, Pitot PA, Tressler RJ, Cushman C, Reynolds MA and Parry TJ: Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors. Clin Cancer Res 6: 2094-2103, 2000. (Pubitemid 30305110)
31. Scherr M, Grez M, Ganser A and Engels JW: Specific hammerhead ribozyme-mediated cleavage of mutant N-ras mRNA in vitro and ex vivo. J Biol Chem 272: 14304-14313, 1997.
32. Wright L and Kearney P: Current status of ribozymes as gene therapy agents for cancer. Cancer Invest 19: 495-509, 2001. (Pubitemid 32619390)
33. Gibson SA, Pellenz C, Hutchison RE, Davey FR and Shillitoe EJ: Induction of apoptosis in oral cancer cells by an anti-bcl-2 ribozyme delivered by an adenovirus vector. Clin Cancer Res 6: 213-222, 2000. (Pubitemid 30064996)
34. Dorai T, Perlman H, Walsh K, Shabsigh A, Goluboff ET, Olsson CA and Buttyan R: A recombinant defective adenoviral agent expressing anti-bcl-2 ribozyme promotes apoptosis of bcl-2-expressing human prostate cancer cells. Int J Cancer 82: 846-852, 1999. (Pubitemid 29384336)
35. Hübinger G, Schmid M, Linortner S, Manegold A, Bergmann L and Maurer U: Ribozyme-mediated cleavage of wt1 transcripts suppresses growth of leukaemia cells. Exp Hematol 29: 1226-1235, 2001. (Pubitemid 32927224)
36. Perlman H, Sata M, Krasinski K, Dorai T, Buttyan R and Walsh K: Adenoviras-encoded hammerhead ribozyme to bcl-2 inhibits neointimal hyperplasia and induces vascular smooth muscle cell apoptosis. Cardiovasc Res 45: 570-578, 2000. (Pubitemid 30047123)
37. Tanabe T, Kuwabara T, Warashina M, Tani K, Taira K and Asano S: Oncogene inactivation in a mouse model. Nature 406: 473-474, 2000.
38. Giannini CD, Roth WK, Piiper A and Zeuzem S: Enzymatic and antisense effects of a specific anti-Ki-ras ribozyme in vitro and in cell culture. Nucleic Acids Res 27: 2737-2744, 1999.
39. Staege MS, Gorelov V, Bulankin A, Fischer U, Dumon K, Hohndorf L, Hattenhorst U, Kramm C and Burdach S: Stable transgenic expression of IL-2 and HSV1-tk by single and fusion tumor cell lines bearing EWS/FLI-1 chimeric genes. Pediatr Hematol Oncol 20: 119-140, 2003. (Pubitemid 36222473)
40. Giard DJ, Aaronson SA, Todaro GJ, Arnstein P, Kersey JH, Dosik H and Parks WP: In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. J Natl Cancer Inst 51: 1417-1423, 1973.
41. Martinez-Ramirez A, Rodriguez-Perales S, Melendez B, Martinez-Delgado B, Urioste M, Cigudosa JC and Benitez J: Characterization of the A673 cell line (Ewing tumor) by molecular cytogenetic techniques. Cancer Genet Cytogenet 141: 138-142, 2003. (Pubitemid 36269213)
42. Bramlage B, Luzi E and Eckstein F: Designing ribozymes for the Inhibition of gene expression. Trends Biotechnol 16: 434-438, 1998. (Pubitemid 28484813)
43. Eckstein F: Searching for ideal partner. Nat Biotechnol 16: 24, 1998.
44. Welch PJ, Barber JR and Wong-Staal F: Expression of ribozymes in gene transfer systems to modulate target RNA levels. Curr Opin Biotechnol 9: 486-496, 1998. (Pubitemid 28478970)
45. Wiechen K, Zimmer C and Dietel M: Selection of a high activity c-erb-2 ribozyme using a fusion gene of c-erb-2 and the enhanced green fluorescent protein. Cancer Gene Ther 5: 45-51, 1998. (Pubitemid 128639990)
46. Bertrand E, Castanotto D, Zhou C, Carbonnelle C, Lee NS, Good P, Chatterjee S, Grange T, Pictet R, Kohn D, Engelke D and Rossi JJ: The expression cassette determines the functional activity of ribozymes in mammalian cells by controlling their intracellular localization. RNA 3: 75-88, 1997. (Pubitemid 27030252)
47. Good PD, Krikos AJ, Li SX, Bertrand E, Lee NS, Giver L, Ellington A, Zaia JA, Rossi JJ and Engelke DR: Expression of small, therapeutic RNAs in human cell nuclei. Gene Ther 4: 45-54, 1997. (Pubitemid 27073222)
48. Koseki S, Tanabe T, Tani K, Asano S, Shioda T, Nagai Y, Shimada T, Ohkawa J and Taira K: Factors governing the activity in vivo of ribozymes transcribed by RNA Polymerase III. J Virol 73: 1868-1877, 1999.
49. Kato Y, Kuwabara T, Warashina M, Toda H and Taira K: Relationships between the activities in vitro and in vivo of various kinds of ribozyme and their intracellular localization in mammalian cells. J Biol Chem 276: 15378-15385, 2001.
50. Kuwabara T, Warashina M, Koseki S, Sano M, Ohkawa J, Nakayama K and Taira K: Significantly higher activity of a cytoplasmic hammerhead ribozyme than a corresponding nuclear counterpart: engineered tRNAs with an extended 3′ end can be exported efficiently and specifically to the cytoplasm in mammalian cells. Nucleic Acids Res 29: 2780-2788, 2001. (Pubitemid 32685041)
51. Thompson DJ, Ayers DF, Malmstrom TA, McKenzie TL, Ganousis L, Chowrira BM, Couture L and Stinchcomb DT: Improved accumulation and activity of ribozymes expressed from a tRNA-based RNA polymerase III promotor. Nucleic Acids Res 23: 2259-2268, 1995.
52. Aigner A, Fischer D, Merdan T, Bras C, Kissel T and Czubayko F: Delivery of unmodified bioactive ribozymes by an RNA-stabilizing polyethylenimine (LMW-PEI) efficiently down-regulates gene expression. Gene Ther 9: 1700-1707, 2002. (Pubitemid 36104614)
53. Borkhardt A: Blocking oncogenes in malignant cells by RNA interference - new hope for a highly specific cancer treatment? Cancer Cell 2: 167-168, 2002.
54. Metzlaff M: RNA-mediated RNA degradation in transgene- and virus-induced gene silencing. Biol Chem 383: 1483-1489, 2002. (Pubitemid 35282969)
55. Scherer LJ and Rossi JJ: Approaches for the sequence-specific knockdown of mRNA. Nat Biotechnol 21: 1457-1465, 2003.